Lartruvo Sarcomas logro una Aprobación Acelerada FDA en 2016 con Resultados de Fase 2. ////// Pero la Fase 3 No ha Confirmado el Objetivo Primario (OS) . Phase 3 trial fails to confirm OS benefit of olaratumab in advanced soft tissue sarcoma .

'Unprecedented' Survival Benefit Vanishes in Confirmatory Cancer Trial .

CHICAGO -- A year-long overall survival (OS) improvement with olaratumab (Lartruvo) in an early-phase soft-tissue sarcoma trial disappeared when the drug was tested in a larger phase III trial.

...